Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
42 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Bionomics Limited - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Bionomics Limited - Product Pipeline Review - 2014', provides an overview of the Bionomics Limited's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Bionomics Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Bionomics Limited including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Bionomics Limited's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Bionomics Limited's pipeline products Reasons to buy - Evaluate Bionomics Limited's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Bionomics Limited in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Bionomics Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Bionomics Limited and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Bionomics Limited - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Bionomics Limited and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Bionomics Limited Snapshot 5 Bionomics Limited Overview 5 Key Information 5 Key Facts 5 Bionomics Limited - Research and Development Overview 6 Key Therapeutic Areas 6 Bionomics Limited - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Out-Licensed Products 11 Out-Licensed Products/Combination Treatment Modalities 12 Bionomics Limited - Pipeline Products Glance 13 Bionomics Limited - Clinical Stage Pipeline Products 13 Phase II Products/Combination Treatment Modalities 13 Phase I Products/Combination Treatment Modalities 14 Bionomics Limited - Early Stage Pipeline Products 15 Preclinical Products/Combination Treatment Modalities 15 Discovery Products/Combination Treatment Modalities 16 Bionomics Limited - Drug Profiles 17 BNC-105 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 BNC-105P 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 BNC-210 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 BL-011256 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 BNC-101 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 BNC-164 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 BNC-420 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 BNC-102 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Programs for Cancer 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Small Molecules to Agonize GABA-A Receptor For Epilepsy 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Small Molecules to Block Nav 1.7 Channels for Chronic And Neuropathic Pain 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Bionomics Limited - Pipeline Analysis 30 Bionomics Limited - Pipeline Products by Target 30 Bionomics Limited - Pipeline Products by Route of Administration 31 Bionomics Limited - Pipeline Products by Molecule Type 32 Bionomics Limited - Pipeline Products by Mechanism of Action 33 Bionomics Limited - Recent Pipeline Updates 34 Bionomics Limited - Dormant Projects 38 Bionomics Limited - Discontinued Pipeline Products 39 Discontinued Pipeline Product Profiles 39 Drug to Inhibit RET Kinase for Lung and Thyroid Cancer 39 Bionomics Limited - Locations And Subsidiaries 40 Head Office 40 Other Locations & Subsidiaries 40 Appendix 41 Methodology 41 Coverage 41 Secondary Research 41 Primary Research 41 Expert Panel Validation 41 Contact Us 42 Disclaimer 42
List of Tables Bionomics Limited, Key Information 5 Bionomics Limited, Key Facts 5 Bionomics Limited - Pipeline by Indication, 2014 7 Bionomics Limited - Pipeline by Stage of Development, 2014 9 Bionomics Limited - Monotherapy Products in Pipeline, 2014 10 Bionomics Limited - Out-Licensed Products in Pipeline, 2014 11 Bionomics Limited - Out-Licensed Products/ Combination Treatment Modalities, 2014 12 Bionomics Limited - Phase II, 2014 13 Bionomics Limited - Phase I, 2014 14 Bionomics Limited - Preclinical, 2014 15 Bionomics Limited - Discovery, 2014 16 Bionomics Limited - Pipeline by Target, 2014 30 Bionomics Limited - Pipeline by Route of Administration, 2014 31 Bionomics Limited - Pipeline by Molecule Type, 2014 32 Bionomics Limited - Pipeline Products by Mechanism of Action, 2014 33 Bionomics Limited - Recent Pipeline Updates, 2014 34 Bionomics Limited - Dormant Developmental Projects,2014 38 Bionomics Limited - Discontinued Pipeline Products, 2014 39 Bionomics Limited, Subsidiaries 40
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.